IGC Pharma, Inc. (IGC)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $20.54M
Last updated: Nov 17, 2026 at 11:05 AM ET
IGC Pharma, Inc. (IGC) Stock Forecast
Analysts expect IGC Pharma (IGC) to earn -$0.09 per share in the fiscal year ending Mar 31, 2027, on revenue of $1.00M. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.08.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Mar 31, 2027
- -$0.09
- EPS consensus, revenue $1.00M
- Fiscal year ending Dec 31, 2027
- -$0.08
- EPS consensus, revenue $958000
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | -$0.09 | -$0.09 to -$0.09 | 1 | $1.00M | $1.00M to $1.00M | 1 |
| Dec 31, 2027 | -$0.08 | -$0.08 to -$0.08 | 1 | $958000 | $958000 to $958000 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.02 | -$0.02 to -$0.02 | 1 | $280000 | $280000 to $280000 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Dec 31, 2026 | 0 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Mar 31, 2027 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$0.09 | -$0.09 | -$0.09 | -$0.09 | -$0.09 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.08 | -$0.09 | -$0.09 | -$0.09 | -$0.09 | N/A |
| Quarter ending Dec 31, 2026 | -$0.02 | -$0.02 | -$0.03 | -$0.03 | -$0.03 | N/A |
Frequently Asked Questions About IGC
What is the IGC stock forecast?
Consensus analyst estimates put IGC Pharma's EPS at -$0.09 for the fiscal year ending Mar 31, 2027, on revenue of $1.00M.
What EPS do analysts expect from IGC next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$0.09, with estimates from -$0.09 to -$0.09 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.08 to -$0.08 from 1 analyst.
What revenue do analysts expect from IGC Pharma next year?
For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $1.00M, with estimates from $1.00M to $1.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $958000, with estimates from $958000 to $958000.
How many analysts cover IGC?
1 analyst estimates EPS for IGC Pharma for the fiscal year ending Mar 31, 2027.
IGC pages: Overview, Earnings, Forecast, Financials, Competitors